Autolus Therapeutics (NASDAQ:AUTL) & Provectus Biopharmaceuticals (OTCMKTS:PVCT) Critical Survey

Autolus Therapeutics (NASDAQ:AUTL) and Provectus Biopharmaceuticals (OTCMKTS:PVCT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.

Volatility & Risk

Autolus Therapeutics has a beta of 1.93, meaning that its stock price is 93% more volatile than the S&P 500. Comparatively, Provectus Biopharmaceuticals has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500.

Profitability

This table compares Autolus Therapeutics and Provectus Biopharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-381.40%	-99.05%	-42.31%
Provectus Biopharmaceuticals	N/A	N/A	-866.72%

Valuation and Earnings

This table compares Autolus Therapeutics and Provectus Biopharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39 million	5.52	-$287.53 million	($1.08)	-1.45
Provectus Biopharmaceuticals	$340,000.00	80.22	-$5.43 million	N/A	N/A

Provectus Biopharmaceuticals has lower revenue, but higher earnings than Autolus Therapeutics.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Autolus Therapeutics and Provectus Biopharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1	1	5	2	2.89
Provectus Biopharmaceuticals	0	0	0	0	0.00

Autolus Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 443.13%. Given Autolus Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Autolus Therapeutics is more favorable than Provectus Biopharmaceuticals.

Insider and Institutional Ownership

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 0.1% of Provectus Biopharmaceuticals shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 12.8% of Provectus Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Autolus Therapeutics beats Provectus Biopharmaceuticals on 9 of the 13 factors compared between the two stocks.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.